Hemostasis News and Research

RSS

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.

30 Oct 2010

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and nine months ended September 30, 2010 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Oct 2010

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.

22 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Orthovita 2010 third quarter increases 5% to $23.3 million

Orthovita, Inc., an orthobiologics and biosurgery company, today announced that product sales for the third quarter of 2010 were $23.3 million, a 5% increase over product sales of $22.3 million in the third quarter of 2009.

21 Oct 2010

Z-Medica enters agreement with two Swedish medical device distributors for QuikClot products

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed exclusive distribution agreements with Vingmed AB and Mediplast AB, two leading Swedish medical device distributors, for distribution of its QuikClot line of hemostatic agents in Sweden, Denmark and Norway for the first time.

From Medica Corporation 21 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Orthovita's Cortoss Bone Augmentation study results to be presented at NASS Annual Meeting

Orthovita, Inc.an orthobiologics and biosurgery company, is pleased to announce that Hyun W. Bae, M.D., of The Spine Institute at Saint John's Health Center in Santa Monica, California, will present an abstract entitled, Correlation of Early Pain and Long-Term Functional Results from a Multi-Center, Prospective, Randomized, Controlled FDA-IDE Vertebroplasty Trial,at the 25th Annual Meeting of the North American Spine Society (NASS) being held October 5-9, 2010 at the Orange County Convention Center in Orlando, Florida.

6 Oct 2010

Ceremed's implantable polymer material receives Best New Technology for Spine Care award

Ceremed's patented implantable polymer material known as AOC won Orthopedics This Week's annual award for Best New Technology for Spine Care in 2010 in the Biomaterials category.

5 Oct 2010

Ceremed awarded NIH SBIR grant to develop soluble carrier for topical delivery of antibiotic Vancomycin

Ceremed, Inc. was awarded a Small Business Innovation Research (SBIR) grant, the company's third in a series of grants from the National Institutes of Health to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents directly to surgical sites. The recently awarded grant will aid Ceremed in its effort to develop a soluble carrier to topically deliver the antibiotic Vancomycin.

5 Oct 2010

FDA clears Orthovita's VITOMATRIX Bone Graft Substitute for dental procedures

Orthovita, Inc., an orthobiologics and biosurgery company, announced that it received 510(k) clearance from the U.S. Food and Drug Administration to market VITOMATRIX Bone Graft Substitute as a bone grafting material in certain dental procedures.

4 Oct 2010

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Benrikal Services to distribute the Bengal Radial Compression Band in the United States.

29 Sep 2010

ENTrigue partners with HemCon to distribute hemostatic surgical gel

HemCon Medical Technologies, a global innovative developer of advanced medical technologies and products, has recently partnered with ENTrigue Surgical, Inc., a leading provider of medical devices and therapies for surgeries of the Ear, Nose and Throat, to develop and distribute HemCon's latest breakthrough product, a hemostatic surgical gel.

23 Sep 2010

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

St. Jude Medical, Inc., a global medical device company, today announced subset data results for the Angio-Seal™ Evolution™ Vascular Closure Device Registry. The results reaffirm the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.

22 Sep 2010

Orthovita publishes clinical data from IDE pilot studies

Orthovita, Inc., an orthobiologics and biosurgery company, is pleased to announce the publication of "Clinical Experience Using Cortoss for Treating Vertebral Compression Fractures with Vertebroplasty and Kyphoplasty" in the September 15, 2010 edition of Spine.

21 Sep 2010

Talecris Biotherapeutics announces 2010 eALTA award recipients

Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).

21 Sep 2010

Fred Hutchinson Cancer Center research team wins 2010 BioFlux Innovation Award

Fluxion Biosciences, Inc. announced today that a research team from Fred Hutchinson Cancer Center has won the 2010 BioFlux Innovation Award competition. Laura Sycuro, Ph.D., a post-doctoral research fellow in the lab of David Fredricks, M.D., authored the winning submission which focuses on screening and characterizing bacterial strains involved in biofilm-related infections known to affect women's reproductive health.

From Fluxion Biosciences 17 Sep 2010

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed an exclusive distribution agreement with Nihon-Kohden, Japan's leading manufacturer, developer and distributor of medical electronic equipment . The agreement allows Nihon-Kohden the exclusive right to distribute Z-Medica's QuikClot line of hemostatic agents to hospital, military and law enforcement markets throughout Japan. The companies have been working together since early 2009 to obtain regulatory approval.

From Medica Corporation 30 Aug 2010

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

26 Aug 2010